Rheumatology

The relationship between depression and medical errors is bidirectional, meaning depressive symptoms may lead to more medical errors in practice and medical errors may lead to the development of or worsened depressive symptoms. In other words, physician well-being is critical to patient care.

In a recent workforce survey of more than 12,000 physicians across 29+ specialties, 50% of rheumatologists reported significant burnout or depression, making rheumatology the second-highest ranking field for burnout (after critical care).

Rheumatoid arthritis is a complex condition. How much do you know about RA treatment?

Jeffrey Curtis, MD, MS, MPH, discusses malignancies in older patients with rheumatoid arthritis and cardiovascular risks being treated with either tofacitinib or tumor necrosis factor (TNF) inhibitors.

Continual improvement was shown in patient-reported pain levels when treated with guselkumab compared with placebo.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending November 12, 2021.

Jeff Peterson, MD, discusses his study determining the complete response rate of pegloticase in conjunction with methotrexate.

Hermine Brunner, MD, MSc, MBA, discusses secukinumab treatment in patients with enthesitis-related arthritis and juvenile psoriatic arthritis.

While statin initiation was associated with reducing the risk of cardiovascular disease, it may increase in the risk of developing diabetes in patients with rheumatoid arthritis.

Closing out their discussion, experts highlight practical advice for caring for patients with SARDs in the current treatment landscape.

An interview on new findings suggesting baseline heart failure may be an indicator of increased mortality risk in patients treating arthritis with the DMARD.

Results show that antimetabolites and BCDT medications were frequently represented in the group of vaccinated patients who were hospitalized for COVID-19.

A team from Vanderbilt identified 4 key predictors from a retrospective analysis of cases since 2020.

Interventions for patients with systemic lupus erythematosus (SLE) need to address physician/patient communication to improve health outcomes, according to Dr. Maheswaranathan.

New ACR findings supporting rheumatology societies' advocacy for more intensive therapy strategies, with proof of safety.

New late-breaking data from ACR 2021 show the mRNA vaccine may differ in patients dependent on their disease.

Patients who are treated with B cell depletion therapies show that their B cell count at time of vaccination can impact their COVID-19 antibody response.

Investigators observed stark contrasts in COVID-19 mRNA vaccination response among inflammatory rheumatic disease patients and the general population.

Late-breaking data from ACR 2021 shows that most of the fully vaccinated patients with breakthrough infections of SARS-COV-2 were on anti-metabolites or BCDT.

An assessment of a rheumatic disease cohort shows Spike protein antibody response is significantly decreased in vaccinated patients, and may vary by treatment.

Patients are increasingly encouraged to take an active role in the management of their chronic conditions. How much do you know about self-management in rheumatoid arthritis?

Lower health literacy has been found to be associated with worsened health outcomes for patients with systemic lupus erythematosus (SLE).

Fetal deaths associated with the rheumatic disease have been on the decline, but increased risks persist nonetheless.

Alopecia and nausea risk may be more easily identified in patients initiating methotrexate for rheumatoid arthritis.

A study presented at ACR 2021 found that CBD had no significant effect on pain intensity in patients with hand osteoarthritis or psoriatic arthritis.

Kyriakos A. Kirou, MD, DSc, FACP, explains the key findings of his upcoming ACR presentation, “COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine.”

An assessment of data from the DISCOVER and VOYAGE trials show the IL-23 inhibitor provides similar safety profiles in patients with either psoriatic disease.

"The primary efficacy endpoint was the proportion of patients with disease control without other immunosuppressants and prednisone-equivalent dose of ≤5 mg/day at week 52," Aranow stated.

Interim data from a post-marketing analysis suggest a boxed label warning for the drug in 2019 may have limited high-risk patients taking the biologic therapy.

A cross-sectional analysis suggests patients with worse social risk scores are significantly more likely to be impacted by juvenile idiopathic arthritis.